Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments, Using Multiomics

Description

The goal of this exploratory study is understand the mechanisms of response to immunotherapy in Non-Small Cell Lung Cancer patients. The investigators are going to search for correlation between specific biological features and response to immunotherapy, and to use those associations for developing an algorithm enabling to identify patients that could benefit from the immune check inhibitor based anti cancer treatment. Patients will provide biological samples before and during their treatment, and clinical data will be collected.

Conditions

Non Small Cell Lung Cancer, Healthy

Study Overview

Study Details

Study overview

The goal of this exploratory study is understand the mechanisms of response to immunotherapy in Non-Small Cell Lung Cancer patients. The investigators are going to search for correlation between specific biological features and response to immunotherapy, and to use those associations for developing an algorithm enabling to identify patients that could benefit from the immune check inhibitor based anti cancer treatment. Patients will provide biological samples before and during their treatment, and clinical data will be collected.

PROPHETIC Extended - Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments, Extended Study.

Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments, Using Multiomics

Condition
Non Small Cell Lung Cancer
Intervention / Treatment

-

Contacts and Locations

Dallas

Baylor Scott and White Research Institute, Dallas, Texas, United States, 75204

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Provision of informed consent prior to any study-specific procedures.
  • * Male or female aged at least 18 years.
  • * ECOG PS - 0/1-2.
  • * Any concurrent and/or other active malignancy that has required systemic treatment within 2 years of first dose of treatment.
  • * Generalized impairment or mental incompetence that would render the patient unable to understand his/her participation in the study.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

OncoHost Ltd.,

Ronan J Kelly, MD MBA, PRINCIPAL_INVESTIGATOR, Chief of Oncology Baylor Scott & White Health System

Study Record Dates

2028-06-30